Ensysce Biosciences, Inc.

NasdaqCM:ENSC Stock Report

Market Cap: US$9.3m

Ensysce Biosciences Valuation

Is ENSC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ENSC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ENSC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ENSC's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ENSC?

Key metric: As ENSC is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ENSC. This is calculated by dividing ENSC's market cap by their current revenue.
What is ENSC's PS Ratio?
PS Ratio2.1x
SalesUS$4.42m
Market CapUS$9.30m

Price to Sales Ratio vs Peers

How does ENSC's PS Ratio compare to its peers?

The above table shows the PS ratio for ENSC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average17x
SNGX Soligenix
24.4x41.1%US$8.9m
AAGH America Great Health
38.7xn/aUS$10.6m
EGRX Eagle Pharmaceuticals
0.03xn/aUS$8.5m
APLM Apollomics
5xn/aUS$10.5m
ENSC Ensysce Biosciences
2.1x121.0%US$9.3m

Price-To-Sales vs Peers: ENSC is good value based on its Price-To-Sales Ratio (2.1x) compared to the peer average (17x).

Price to Sales Ratio vs Industry

How does ENSC's PS Ratio compare vs other companies in the US Biotechs Industry?

145 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.10.3x21.3%
ENSC Ensysce Biosciences
 2.1x121.0%US$9.30m
AMGN Amgen
4.7x2.4%US$152.45b
GILD Gilead Sciences
3.9x2.4%US$110.17b
ENSC 2.1xIndustry Avg. 10.3xNo. of Companies145PS020406080100+
145 CompaniesEstimated GrowthMarket Cap
Industry Avg.10.3x28.3%
ENSC Ensysce Biosciences
 2.1x106.7%US$9.30m
No more companies

Price-To-Sales vs Industry: ENSC is good value based on its Price-To-Sales Ratio (2.1x) compared to the US Biotechs industry average (10.3x).

Price to Sales Ratio vs Fair Ratio

What is ENSC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ENSC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.1x
Fair PS Ratio63.4x

Price-To-Sales vs Fair Ratio: ENSC is good value based on its Price-To-Sales Ratio (2.1x) compared to the estimated Fair Price-To-Sales Ratio (63.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ENSC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.67
US$6.80
+914.3%
26.5%US$8.60US$5.00n/a2
Sep ’25US$0.40
US$9.05
+2,191.1%
5.0%US$9.50US$8.60n/a2
Aug ’25US$0.46
US$13.38
+2,791.9%
29.0%US$17.25US$9.50n/a2
Jul ’25US$0.50
US$13.38
+2,576.1%
29.0%US$17.25US$9.50n/a2
Jun ’25US$0.57
US$13.38
+2,226.1%
29.0%US$17.25US$9.50n/a2
May ’25US$0.61
US$13.50
+2,120.4%
29.6%US$17.50US$9.50n/a2
Apr ’25US$0.78
US$11.33
+1,353.0%
39.5%US$17.50US$7.00n/a3
Mar ’25US$0.92
US$11.65
+1,163.4%
39.9%US$16.30US$7.00n/a2
Feb ’25US$1.48
US$13.60
+818.9%
34.5%US$17.50US$7.00n/a3
Jan ’25US$1.06
US$13.60
+1,183.0%
34.5%US$17.50US$7.00n/a3
Dec ’24US$0.91
US$12.25
+1,244.7%
42.9%US$17.50US$7.00n/a2
Nov ’24US$0.88
US$12.43
+1,306.2%
43.7%US$17.85US$7.00US$0.652
Oct ’24US$1.38
US$12.43
+800.4%
43.7%US$17.85US$7.00US$0.232
Sep ’24US$1.80
US$13.43
+645.8%
33.0%US$17.85US$9.00US$0.402
Aug ’24US$2.07
US$13.43
+548.6%
33.0%US$17.85US$9.00US$0.462
Jul ’24US$1.80
US$16.43
+812.5%
8.7%US$17.85US$15.00US$0.502
Jun ’24US$2.41
US$16.43
+581.5%
8.7%US$17.85US$15.00US$0.572
May ’24US$3.68
US$29.40
+698.9%
49.0%US$43.80US$15.00US$0.612
Apr ’24US$4.86
US$69.90
+1,338.3%
37.3%US$96.00US$43.80US$0.782
Mar ’24US$5.76
US$69.90
+1,113.5%
37.3%US$96.00US$43.80US$0.922
Feb ’24US$8.57
US$79.80
+831.4%
20.3%US$96.00US$63.60US$1.482
Jan ’24US$9.00
US$79.80
+786.7%
20.3%US$96.00US$63.60US$1.062
Dec ’23US$29.64
US$192.00
+547.8%
50.0%US$288.00US$96.00US$0.912
Nov ’23US$40.08
US$1,920.00
+4,690.4%
50.0%US$2,880.00US$960.00US$0.882

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

IQVIA Holdings

US$35.0b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$192.68

7D

-12.1%

1Y

-5.9%

Teva Pharmaceutical Industries

US$18.6b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.43

7D

-4.0%

1Y

81.5%

Collegium Pharmaceutical

US$954.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$29.58

7D

-8.0%

1Y

17.7%